- Home
- HCC vs MIRM Comparison
HCC vs MIRM Comparison
Compare HCC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- MIRM
- Stock Information
- Founded
- HCC 2015
- MIRM 2018
- Country
- HCC United States
- MIRM United States
- Employees
- HCC N/A
- MIRM 334
- Industry
- HCC Coal Mining
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- MIRM Health Care
- Exchange
- HCC Nasdaq
- MIRM Nasdaq
- Market Cap
- HCC 2.5B
- MIRM 2.2B
- IPO Year
- HCC 2017
- MIRM 2019
- Fundamental
- Price
- HCC $46.07
- MIRM $44.86
- Analyst Decision
- HCC Strong Buy
- MIRM Strong Buy
- Analyst Count
- HCC 5
- MIRM 12
- Target Price
- HCC $70.25
- MIRM $63.17
- AVG Volume (30 Days)
- HCC 871.0K
- MIRM 397.1K
- Earning Date
- HCC 04-30-2025
- MIRM 05-07-2025
- Dividend Yield
- HCC 0.70%
- MIRM N/A
- EPS Growth
- HCC N/A
- MIRM N/A
- EPS
- HCC 2.01
- MIRM N/A
- Revenue
- HCC $1,319,451,000.00
- MIRM $379,251,000.00
- Revenue This Year
- HCC N/A
- MIRM $33.98
- Revenue Next Year
- HCC $31.98
- MIRM $16.19
- P/E Ratio
- HCC $22.57
- MIRM N/A
- Revenue Growth
- HCC N/A
- MIRM 69.31
- 52 Week Low
- HCC $38.00
- MIRM $23.83
- 52 Week High
- HCC $75.53
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- HCC 47.06
- MIRM 56.31
- Support Level
- HCC $44.81
- MIRM $43.30
- Resistance Level
- HCC $48.68
- MIRM $44.57
- Average True Range (ATR)
- HCC 1.75
- MIRM 1.20
- MACD
- HCC -0.13
- MIRM -0.05
- Stochastic Oscillator
- HCC 33.11
- MIRM 54.57
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.